Skip to main content
. Author manuscript; available in PMC: 2011 Mar 10.
Published in final edited form as: Sci Signal. 2010 Apr 6;3(116):ra26. doi: 10.1126/scisignal.2000722

Fig. 6. CCM3 mutants found in human patients destabilize VEGFR2 and inhibit VEGFR2 signaling.

Fig. 6

(A) CCM3 mutants do not activate VEGFR2 signaling. VEGFR2 was cotransfected with various CCM3 mutants. Phosphorylation of VEGFR2 and p-PLC-γ were determined. The relative abundance of p-VEGFR2, VEGFR2, as well as the ratio of p-PLC-γ/PLC-γ are shown, with each control group set as 1.0. Data are mean ± SEM from four independent blots. *, p<0.05. (D) CCM3, but not CCM2, stabilizes and activates VEGFR2. VEGFR2 was cotransfected with CCM3 or CCM2. Phosphorylated and total VEGFR2 were determined and quantified as in (C). The relative abundance of p-VEGFR2 and VEGFR2 are shown, with each control group set as 1.0. Data are mean ± SEM from four independent blots. *, p<0.05.